【先声药业:乐德奇拜单抗上市申请获国家药监局受理,用于治疗特应性皮炎】7月8日,先声药业与康乃德生物医药合作的创新药乐德奇拜单抗新药上市申请获国家药品监督管理局受理,用于治疗特应性皮炎。乐德奇拜单抗是靶向IL-4Rα的全人源单抗。

金融界
09 Jul
7月8日,先声药业与康乃德生物医药合作的创新药乐德奇拜单抗新药上市申请获国家药品监督管理局受理,用于治疗特应性皮炎。乐德奇拜单抗是靶向IL-4Rα的全人源单抗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10